ESR1 and breast cancer: With this in mind, we argue that there is a good opportunity to improve outcomes in the HER2+ brain metastatic subset following treatment with trastuzumab, pertuzumab, and a cell cycle inhibitor, especially in ER+/HER2+ BC patients.